Concepedia

Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan

Masahide Kondo, Shu-Ling Hoshi, Hiroshi Ishiguro, Masakazu Toi

Breast Cancer Research and Treatment · 2012 · 26 citations · 20 references

DOI

Concepts

References

20

Gene expression profiling predicts clinical outcome of breast cancer

Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text

, , +16

A Gene-Expression Signature as a Predictor of Survival in Breast Cancer

Marc J. van de Vijver, Yudong D. He, Laura van ‘t Veer et al. · New England Journal of Medicine · 2002 · 6.5K citations · Full text

, , +17

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Aron Goldhirsch, Eric P. Winer, Alan S. Coates et al. · Annals of Oncology · 2013 · 3.7K citations · Full text

, , +10

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

Aron Goldhirsch, James N. Ingle, Richard D. Gelber et al. · Annals of Oncology · 2009 · 1.4K citations · Full text

, , +16

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Marc Buyse, Sherene Loi, Laura van’t Veer et al. · JNCI Journal of the National Cancer Institute · 2006 · 1.2K citations · Full text

, , +14